Registry Can Reduce CRE Carriers, CRE Prevalence
FRIDAY, May 10, 2019 -- The implementation of a registry can reduce the spread of carbapenem-resistant Enterobacteriaceae (CRE), even when only a proportion of facilities participate, according to a study published online May 9 in Clinical Infectious Diseases.
Bruce Y. Lee, M.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues developed an agent-based model of all inpatient health care facilities in the Chicago metropolitan area, surrounding area, and patient flow. The impact of a registry that tracked patients carrying CRE to help guide infection prevention and control was explored in different scenarios.
The researchers found that the registry reduced the number of new carriers by 11.7 percent and reduced CRE prevalence by 7.6 percent during a three-year period when all 402 Illinois facilities participated. Registry use resulted in an 11.6 percent relative reduction in new carriers (16.9 and 1.2 percent in participating and nonparticipating facilities, respectively) and a 5.0 percent relative reduction in prevalence when 75 percent of the largest Illinois facilities participated. There were relative reductions of 10.7 and 5.6 percent in incident carriers and prevalence, respectively, when 50 percent participated and relative reductions of 9.1 (20.4 and 1.6 percent in participants and nonparticipating facilities, respectively) and 2.8 percent, respectively, when 25 percent participated.
"We found that a registry can provide independent effects of disease prevention, even before additional public health prevention measures are implemented," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: May 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.